Hims & Hers Health and certain executives face a proposed securities class action after a July 29, 2026, Federal Trade Commission complaint filed with Utah and Los Angeles County alleging privacy, billing and cancellation violations. The securities allegations concern statements about health-data safeguards, business practices, operations and prospects, including claims that Hims shared sensitive consumer health information with third-party advertising platforms such as Meta and Snap, charged for prescriptions shortly after intake forms were submitted, and used subscription practices that violated the Restore Online Shoppers' Confidence Act. Hims shares fell $4.32, or 14.7%, on the news, reducing market capitalization by more than $970 million. Hagens Berman is investigating related claims, while Robbins Geller announced the lead-plaintiff opportunity in Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313, pending in the Northern District of California. Schall, Brown & Schwartz LLP, the Law Offices of Frank R. Cruz and Kessler Topaz Meltzer & Check LLP separately publicized the action on Sept. 4, 2026. Investors do not need to serve as lead plaintiff to participate in any potential recovery.